InMed Pharmaceuticals Inc. (MTRI) stock
MTRINasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as INM
$15.61+3.41 (+27.94%)
Close on Nov 11, 2026Market cap $85.75MP/E –Yield –
InMed Pharmaceuticals EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
InMed Pharmaceuticals's EPS for the twelve months ending Sep 30, 2026 was -$2.90. For fiscal 2026 it was -$3.12. The highest annual figure on record is -$3.12 in fiscal 2026.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | -$3.12 | – |
| FY2025 | Jun 30, 2025 | -$8.36 | – |
| FY2024 | Jun 30, 2024 | -$20.14 | – |
| FY2023 | Jun 30, 2023 | -$65.00 | – |
| FY2022 | Jun 30, 2022 | -$663.40 | – |
| FY2021 | Jun 30, 2021 | -$759.20 | – |
| FY2020 | Jun 30, 2020 | -$855.00 | – |
Quarterly eps
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ3 2026 | Sep 30, 2026 | -$0.42 | – |
| Q4 FY2026CQ2 2026 | Jun 30, 2026 | -$1.24 | – |
| Q3 FY2026CQ1 2026 | Mar 31, 2026 | -$0.73 | – |
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | -$0.51 | – |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | -$0.44 | – |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | -$1.94 | – |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | -$3.64 | – |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | -$2.71 | – |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | -$3.58 | – |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | -$3.71 | – |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | -$15.24 | – |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | -$12.00 | – |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | -$18.20 | – |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | -$81.20 | – |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | -$244.40 | – |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | -$122.80 | – |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | -$154.60 | – |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | -$123.40 | – |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | -$202.51 | – |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | -$205.00 | – |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | -$185.00 | – |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | -$155.00 | – |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | -$154.80 | – |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | -$195.00 | – |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | -$240.00 | – |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | -$270.00 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?